Sarah Premji/X
Jun 1, 2025, 16:02
Sarah Premji Shares ASCENT-04 Trial Outcomes in First-Line TNBC Treatment at ASCO 2025
Sarah Premji, Clinical Oncology Fellow at Mayo Clinic, posted on X:
“ASCENT-04 met TNBC evaluating use of sacituzumab +pembro vs chemo + pembro in the 1st line.
baseline 50% lung 25% liver mets
11.2 mo vs 7.8 mo imp in mPFS
Longer DOR 16.5 mo vs 9.2 mo and higher ORR
no inc irAE
New potential SOC!”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 11:05
Jul 19, 2025, 10:29
Jul 19, 2025, 10:12
Jul 19, 2025, 09:55
Jul 19, 2025, 09:05
Jul 19, 2025, 08:54
Jul 19, 2025, 07:24
Jul 19, 2025, 07:23